David McDonnell

2.0k citations
68 papers · 1.4k · h-index 20

Impact in

Papers in

Co-authors
Holland C. Detke (20 shared papers)Daniel Lin (3 shared papers)Richard F. Bergstrom (2 shared papers)Adam Simmons (16 shared papers)Ying Jiang (18 shared papers)Fangyi Zhao (6 shared papers)John Michael Kane (3 shared papers)Lauren DiPetrillo (13 shared papers)
Journals
BMC Psychiatry (9 papers)CNS Spectrums (7 papers)Schizophrenia Research (6 papers)The Journal of Clinical Psychiatry (6 papers)European Neuropsychopharmacology (3 papers)
Partner nations
United StatesIrelandGermany

In The Last Decade

David McDonnell

66 papers receiving 1.4k citations

Peers

David McDonnell
Comparison fields: 5 of 71
  • Psychiatry and Mental health 1.0k
  • Biological Psychiatry 58
  • Pharmacology 233
  • Neurology 89
  • Philosophy 74
Replace Keith Karcher with:
Keith Karcher United States
Holland C. Detke United States
Thomas J. Arndt United States
Maju Mathews United States
Mary Anne Dellva United States
Matthew A. Fuller United States
Andreas Schreiner Germany
Shlomo Brook South Africa
Robert L. Dufresne United States
Jolene R. Bostwick United States
David McDonnell relative to Keith Karcher United States Keith Karcher's profile →
Citations per field
00.5×2×2.8×
Keith Karcher · 1×
Citations per year

Countries citing papers authored by David McDonnell

Since Specialization
Citations

This map shows the geographic impact of David McDonnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David McDonnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David McDonnell more than expected).

Fields of papers citing papers by David McDonnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David McDonnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David McDonnell. The network helps show where David McDonnell may publish in the future.

Co-authors

The 25 scholars most cited alongside David McDonnell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David McDonnell Line = papers co-authored together David McDonnell links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
American Journal of Psychiatry ·John Michael Kane, Holland C. Detke, Dieter Naber, Gopalan Sethuraman, Daniel Lin, Richard F. Bergstrom, David McDonnell
2009165
2
An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia
The Journal of Clinical Psychiatry ·John Lauriello, Tim J R Lambert, Scott W. Andersen, Daniel Lin, Cindy Coe Taylor, David McDonnell
2008101
3
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
BMC Psychiatry ·Holland C. Detke, David McDonnell, Fangyi Zhao, Sebastian Sorsaburu, Victoria Jennifer Stefaniak, Sara A. Corya +1 other
201098
4
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression
The British Journal of Psychiatry ·Mauricio F. Tohen, David McDonnell, Michael G. Case, Shigenobu Kanba, Kyooseob Ha, Yi Fang, Hideaki Katagiri, Juan Carlos Gómez
201298
5
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
American Journal of Psychiatry ·Christoph Ulrich Correll, John W. Newcomer, Bernard L. Silverman, Lauren DiPetrillo, Christine E. Graham, Ying Jiang, Yangchun Du, Adam Simmons
202093
6
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
BMC Psychiatry ·David McDonnell, Holland C. Detke, Richard F. Bergstrom, Prajakti A. Kothare, Jason T. Johnson, Mary P. Stickelmeyer, Manuel Sánchez-Félix, Sebastian Sorsaburu
201074
7
Classifying Patients by Antipsychotic Adherence Patterns Using Latent Class Analysis: Characteristics of Nonadherent Groups in the California Medicaid (Medi-Cal) Program
Value in Health ·Jeonghoon Ahn, Jeffrey S. McCombs, Changun Jung, Tim J. Croudace, David McDonnell, Haya Ascher‐Svanum, Eric T. Edgell, Lizheng Shi
200763
8
D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia
Neuropsychopharmacology ·David C. Mamo, Shitij Kapur, Matcheri S. Keshavan, Marc A. Laruelle, Cindy Coe Taylor, Prajakti A. Kothare, Penny Barsoum, David McDonnell
200758
9
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
Neuropsychiatric Disease and Treatment ·Leslie Citrome, Joseph P. McEvoy, Mark S. Todtenkopf, David McDonnell, Peter Weiden
201956
10
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia
The Journal of Clinical Psychiatry ·Steven G. Potkin, Jelena L. Kunovac, Bernard L. Silverman, Adam Simmons, Ying Jiang, Lauren DiPetrillo, David McDonnell
202048
11
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
Schizophrenia Research ·René S. Kahn, Bernard L. Silverman, Lauren DiPetrillo, Christine E. Graham, Ying Jiang, Jiani C. Yin, Adam Simmons, Vasudev Bhupathi
202135
12
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia
Clinical Therapeutics ·Lei Sun, David McDonnell, Lisa Von Moltke
201832
13
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder
International Clinical Psychopharmacology ·David McDonnell, John Landry, Holland C. Detke
201427
14
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long‐acting injection versus oral olanzapine
Human Psychopharmacology Clinical and Experimental ·David McDonnell, Ludmila A. Kryzhanovskaya, Fangyi Zhao, Holland C. Detke, Peter D. Feldman
201125
15
Dose correspondence between olanzapine long-acting injection and oral olanzapine
International Clinical Psychopharmacology ·Holland C. Detke, Fangyi Zhao, Parag Garhyan, Janice L. Carlson, David McDonnell
201023
16
Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
Clinical Pharmacology in Drug Development ·Lei Sun, David McDonnell, Jianjun Liu, Lisa Von Moltke
201822
17
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
Schizophrenia Bulletin ·Christoph Ulrich Correll, Evan A. Stein, Christine E. Graham, Lauren DiPetrillo, Sarah C. Akerman, Arielle D. Stanford, Ying Jiang, Sergey Yagoda
202221
18
Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia
Clinical Therapeutics ·Malcolm I. Mitchell, Prajakti A. Kothare, Richard Bergstrom, Fangyi Zhao, Kai Yu Jen, Daniel J. Walker, Jason T. Johnson, David McDonnell
201321
19
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
CNS Spectrums ·Sergey Yagoda, Christine E. Graham, Adam Simmons, Christina Arevalo, Ying Jiang, David McDonnell
202021
20
Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder
BMC Psychiatry ·Michael J. Doane, Leona Bessonova, Haley S. Friedler, Harry Cheng, Thomas Brecht, Amy K. O’Sullivan, Hannah C. Cummings, David McDonnell
202220

About David McDonnell

David McDonnell is a scholar working on Psychiatry and Mental health, Pharmacology, Biological Psychiatry, Physiology and Cardiology and Cardiovascular Medicine, having authored 68 papers that have together received 1.4k indexed citations. Recurring topics across this work include Schizophrenia research and treatment (50 papers), Bipolar Disorder and Treatment (15 papers), Treatment of Major Depression (14 papers), Diet and metabolism studies (5 papers), Tryptophan and brain disorders (4 papers), Electroconvulsive Therapy Studies (4 papers), Pharmaceutical studies and practices (2 papers) and Analytical Methods in Pharmaceuticals (2 papers). The work is most often cited by research in Psychiatry and Mental health (1.0k citations), Biological Psychiatry (58 citations), Pharmacology (233 citations), Neurology (89 citations) and Philosophy (74 citations). David McDonnell has collaborated with scholars based in United States, Ireland and Germany. Frequent co-authors include Holland C. Detke, Daniel Lin, Richard F. Bergstrom, Adam Simmons, Ying Jiang, Fangyi Zhao, John Michael Kane, Lauren DiPetrillo, Lei Sun and Dieter Naber. Their work appears in journals such as BMC Psychiatry, CNS Spectrums, Schizophrenia Research, The Journal of Clinical Psychiatry and European Neuropsychopharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keith KarcherBreakdown of academic impact, for papers by Holland C. DetkeBreakdown of academic impact, for papers by Thomas J. ArndtBreakdown of academic impact, for papers by Maju MathewsBreakdown of academic impact, for papers by Mary Anne DellvaBreakdown of academic impact, for papers by Matthew A. FullerBreakdown of academic impact, for papers by Andreas SchreinerBreakdown of academic impact, for papers by Shlomo BrookBreakdown of academic impact, for papers by Robert L. DufresneBreakdown of academic impact, for papers by Jolene R. Bostwick